Home  |  Contact

Cellosaurus PANC-1 (CVCL_0480)

[Text version]

Cell line name PANC-1
Synonyms Panc-1; PANC.1; Panc 1; PanC1; Panc1; PANC1; Panc-1-P
Accession CVCL_0480
Resource Identification Initiative To cite this cell line use: PANC-1 (RRID:CVCL_0480)
Comments Part of: AKT genetic alteration cell panel (ATCC TCP-1029).
Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: ENCODE project common cell types; tier 3.
Part of: KuDOS 95 cell line panel.
Part of: MD Anderson Cell Lines Project.
Characteristics: Has lost chromosome Y.
Doubling time: 25.83 +- 2.03 hours (PubMed=25394408); 52 hours (CLS); ~42 hours (DSMZ); ~32 hours (PBCF); 15.02 hours (https://www.synapse.org/#!Synapse:syn2347014).
Omics: Array-based CGH.
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: H3K4me3 ChIP-seq epigenome analysis.
Omics: Metabolome analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: Proteome analysis by 2D-DE/MS.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Caution: Additional TP53 mutation in c.815T>C indicated incorrectly in PubMed=1630814.
Sequence variations Homozygous for CDKN2A deletion (PubMed=11787853; PubMed=15367885).
Heterozygous for KRAS p.Gly12Asp (c.35G>A) (PubMed=7809022; PubMed=8026879; PubMed=11115575; PubMed=11787853; PubMed=15367885; PubMed=21607521; CCLE).
Homozygous for TP53 p.Arg273His (c.818G>A) (PubMed=1630814; PubMed=1764370; PubMed=8026879; PubMed=11115575; PubMed=11787853; PubMed=15367885; PubMed=21607521; CCLE).
HLA typing Source: PubMed=9023415
Class I
HLA-AA*02:01,11:01
HLA-BB*38,01
HLA-CC*12,03
Genome ancestry Source: PubMed=30894373

Origin% genome
African2.26
Native American0
East Asian, North2.09
East Asian, South0
South Asian0
European, North60
European, South35.65
Disease Pancreatic ductal adenocarcinoma (NCIt: C9120)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_1778 (1.1B4)CVCL_2257 (1.1E7)CVCL_2259 (1.4E7)
CVCL_3002 (KP-1N)CVCL_WL48 (PANC-1-Cas9-554)CVCL_WL49 (PANC-1-Cas9-555)
CVCL_WL50 (PANC-1-Cas9-556)CVCL_WL51 (PANC-1-Cas9-557)CVCL_WL52 (PANC-1-Cas9-558)
CVCL_WL53 (PANC-1-Cas9-559)CVCL_VQ69 (Panc-1-CTC)CVCL_WS13 (PANC-1RG7)
CVCL_0Q68 (Panc1-MUC1)
Sex of cell Male
Age at sampling 56Y
Category Cancer cell line
STR profile Source(s): AddexBio; ATCC; CCRID; CLS; DSMZ; ECACC; KCLB; PubMed=25877200; RCB; TKG

Markers:
AmelogeninX
CSF1PO10,12
D2S44110,14
D2S133823,24
D3S135817
D5S81811,13
D6S104311,12
D7S8208,10
D8S117914,15
D12S39122
D13S31711
D16S53911
D18S5112
D19S43311,16
D21S1128
FGA21
Penta D14
Penta E7,14
TH017,8
TPOX8,11
vWA15

Run an STR similarity search on this cell line
Web pages http://www.pawefish.path.cam.ac.uk/PancCellLineDescriptions/PANC-1.html
http://dpsc.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=PANC-1
https://physics.cancer.gov/docs/bioresource/pancreas/NCI-PBCF-CRL1469_PANC-1_SOP-508.pdf
http://genome.ucsc.edu/ENCODE/protocols/cell/human/PANC-1_Myers_protocol.pdf
https://strap.nci.nih.gov/celline_detail.php?sample_id=65
http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/p/cell-lines-detail-179.html
http://tcpaportal.org/mclp/
https://www.phe-culturecollections.org.uk/media/120309/panc-1-cell-line-profile.pdf
http://www.cellresource.cn/fdetail.aspx?id=23
http://www.cellresource.cn/fdetail.aspx?id=666
http://www.cellresource.cn/fdetail.aspx?id=1287
http://www.cellresource.cn/fdetail.aspx?id=1986
http://www.cellresource.cn/fdetail.aspx?id=2189
Publications

PubMed=1140870; DOI=10.1002/ijc.2910150505
Lieber M.M., Mazzetta J., Nelson-Rees W.A., Kaplan M., Todaro G.J.
Establishment of a continuous tumor-cell line (PANC-1) from a human carcinoma of the exocrine pancreas.
Int. J. Cancer 15:741-747(1975)

PubMed=6435863
Chang B.K., Black O. Jr., Gutman R.
Inhibition of growth of human or hamster pancreatic cancer cell lines by alpha-difluoromethylornithine alone and combined with cis-diamminedichloroplatinum(II).
Cancer Res. 44:5100-5104(1984)

PubMed=1764370; DOI=10.1038/bjc.1991.467
Barton C.M., Staddon S.L., Hughes C.M., Hall P.A., O'Sullivan C., Kloppel G., Theis B., Russell R.C.G., Neoptolemos J., Williamson R.C.N., Lane D.P., Lemoine N.R.
Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer.
Br. J. Cancer 64:1076-1082(1991)

PubMed=1630814
Ruggeri B., Zhang S.-Y., Caamano J., DiRado M., Flynn S.D., Klein-Szanto A.J.P.
Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes.
Oncogene 7:1503-1511(1992)

PubMed=7809022; DOI=10.1097/00006676-199409000-00018
Sumi S., Beauchamp R.D., Townsend C.M. Jr., Pour P.M., Ishizuka J., Thompson J.C.
Lovastatin inhibits pancreatic cancer growth regardless of RAS mutation.
Pancreas 9:657-661(1994)

PubMed=8026879; DOI=10.1002/ijc.2910580207
Berrozpe G., Schaeffer J., Peinado M.A., Real F.X., Perucho M.
Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer.
Int. J. Cancer 58:185-191(1994)

PubMed=8286197; DOI=10.1038/bjc.1994.24
Lohr M., Trautmann B., Gottler M., Peters S., Zauner I., Maillet B., Kloppel G.
Human ductal adenocarcinomas of the pancreas express extracellular matrix proteins.
Br. J. Cancer 69:144-151(1994)

PubMed=21607521; DOI=10.3892/or.1.6.1223
Iguchi H., Morita R., Yasuda D., Takayanagi R., Ikeda Y., Takada Y., Shimazoe T., Nawata H., Kono A.
Alterations of the p53 tumor-suppressor gene and ki-ras oncogene in human pancreatic cancer-derived cell-lines with different metastatic potential.
Oncol. Rep. 1:1223-1227(1994)

PubMed=9023415; DOI=10.1006/cimm.1996.1062
Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.
HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.
Cell. Immunol. 175:101-110(1997)

PubMed=10027410; DOI=10.1016/S0002-9440(10)65298-4
Ghadimi B.M., Schrock E., Walker R.L., Wangsa D., Jauho A., Meltzer P.S., Ried T.
Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas.
Am. J. Pathol. 154:525-536(1999)

PubMed=11115575; DOI=10.3892/or.8.1.89
Sun C., Yamato T., Furukawa T., Ohnishi Y., Kijima H., Horii A.
Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines.
Oncol. Rep. 8:89-92(2001)

PubMed=11169957; DOI=10.1002/1097-0215(200002)9999:9999<::AID-IJC1014>3.0.CO;2-U
Wallrapp C., Hahnel S., Boeck W., Soder A., Mincheva A., Lichter P., Leder G., Gansauge F., Sorio C., Scarpa A., Gress T.M.
Loss of the Y chromosome is a frequent chromosomal imbalance in pancreatic cancer and allows differentiation to chronic pancreatitis.
Int. J. Cancer 91:340-344(2001)

PubMed=11169959; DOI=10.1002/1097-0215(200002)9999:9999<::AID-IJC1049>3.0.CO;2-C
Sirivatanauksorn V., Sirivatanauksorn Y., Gorman P.A., Davidson J.M., Sheer D., Moore P.S., Scarpa A., Edwards P.A.W., Lemoine N.R.
Non-random chromosomal rearrangements in pancreatic cancer cell lines identified by spectral karyotyping.
Int. J. Cancer 91:350-358(2001)

PubMed=11787853; DOI=10.1007/s004280100474
Moore P.S., Sipos B., Orlandini S., Sorio C., Real F.X., Lemoine N.R., Gress T.M., Bassi C., Kloppel G., Kalthoff H., Ungefroren H., Lohr M., Scarpa A.
Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.
Virchows Arch. 439:798-802(2001)

PubMed=12692724; DOI=10.1007/s00428-003-0784-4
Sipos B., Moser S., Kalthoff H., Torok V., Lohr M., Kloppel G.
A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform.
Virchows Arch. 442:444-452(2003)

PubMed=12800145; DOI=10.1002/gcc.10218
Adelaide J., Huang H.-E., Murati A., Alsop A.E., Orsetti B., Mozziconacci M.-J., Popovici C., Ginestier C., Letessier A., Basset C., Courtay-Cahen C., Jacquemier J., Theillet C., Birnbaum D., Edwards P.A.W., Chaffanet M.
A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.
Genes Chromosomes Cancer 37:333-345(2003)

PubMed=14695172
Iacobuzio-Donahue C.A., Ashfaq R., Maitra A., Adsay N.V., Shen-Ong G.L., Berg K., Hollingsworth M.A., Cameron J.L., Yeo C.J., Kern S.E., Goggins M., Hruban R.H.
Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies.
Cancer Res. 63:8614-8622(2003)

PubMed=15126341; DOI=10.1158/0008-5472.CAN-03-3159
Heidenblad M., Schoenmakers E.F.P.M., Jonson T., Gorunova L., Veltman J.A., van Kessel A.G., Hoglund M.
Genome-wide array-based comparative genomic hybridization reveals multiple amplification targets and novel homozygous deletions in pancreatic carcinoma cell lines.
Cancer Res. 64:3052-3059(2004)

PubMed=15367885; DOI=10.1097/00006676-200410000-00004
Loukopoulos P., Kanetaka K., Takamura M., Shibata T., Sakamoto M., Hirohashi S.
Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity.
Pancreas 29:193-203(2004)

PubMed=15688027; DOI=10.1038/sj.onc.1208383
Heidenblad M., Lindgren D., Veltman J.A., Jonson T., Mahlamaki E.H., Gorunova L., van Kessel A.G., Schoenmakers E.F.P.M., Hoglund M.
Microarray analyses reveal strong influence of DNA copy number alterations on the transcriptional patterns in pancreatic cancer: implications for the interpretation of genomic amplifications.
Oncogene 24:1794-1801(2005)

PubMed=15770730; DOI=10.3748/wjg.v11.i10.1521
Ma J.-H., Patrut E., Schmidt J., Knaebel H.-P., Buchler M.W., Marten A.
Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma.
World J. Gastroenterol. 11:1521-1528(2005)

PubMed=18298655; DOI=10.1111/j.1582-4934.2008.00289.x
Pilarsky C., Ammerpohl O., Sipos B., Dahl E., Hartmann A., Wellmann A., Braunschweig T., Lohr M., Jesenofsky R., Friess H., Wente M.N., Kristiansen G., Jahnke B., Denz A., Ruckert F., Schackert H.K., Kloppel G., Kalthoff H., Saeger H.-D., Grutzmann R.
Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling.
J. Cell. Mol. Med. 12:2823-2835(2008)

PubMed=18380791; DOI=10.1111/j.1349-7006.2008.00779.x
Suzuki A., Shibata T., Shimada Y., Murakami Y., Horii A., Shiratori K., Hirohashi S., Inazawa J., Imoto I.
Identification of SMURF1 as a possible target for 7q21.3-22.1 amplification detected in a pancreatic cancer cell line by in-house array-based comparative genomic hybridization.
Cancer Sci. 99:986-994(2008)

PubMed=18575732; DOI=10.3892/or.20.1.155
Kawaoka T., Oka M., Takashima M., Ueno T., Yamamoto K., Yahara N., Yoshino S., Hazama S.
Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1.
Oncol. Rep. 20:155-163(2008)

CLPUB00416
Oberlin L.
Treatment of pancreatic carcinoma cell lines in vitro and vivo with a monoclonal antibody against the transferrin receptor.
Thesis VMD (2009), Justus-Liebig-Universitat Giessen, Germany

DOI=10.4172/jpb.1000057
Masayo Y., Kiyonaga F., Koji K., Setsuo H., Tadashi K.
The proteomic profile of pancreatic cancer cell lines corresponding to carcinogenesis and metastasis.
J. Proteomics Bioinform. 2:1-18(2009)

PubMed=20418756; DOI=10.1097/MPA.0b013e3181c15963
Deer E.L., Gonzalez-Hernandez J., Coursen J.D., Shea J.E., Ngatia J., Scaife C.L., Firpo M.A., Mulvihill S.J.
Phenotype and genotype of pancreatic cancer cell lines.
Pancreas 39:425-435(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224
Marcotte R., Brown K.R., Suarez F., Sayad A., Karamboulas K., Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.Y., van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J., Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P., Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L., Rottapel R., Neel B.G., Moffat J.
Essential gene profiles in breast, pancreatic, and ovarian cancer cells.
Cancer Discov. 2:172-189(2012)

PubMed=23325432; DOI=10.1101/gr.147942.112
Varley K.E., Gertz J., Bowling K.M., Parker S.L., Reddy T.E., Pauli-Behn F., Cross M.K., Williams B.A., Stamatoyannopoulos J.A., Crawford G.E., Absher D.M., Wold B.J., Myers R.M.
Dynamic DNA methylation across diverse human cell lines and tissues.
Genome Res. 23:555-567(2013)

PubMed=25167228; DOI=10.1038/bjc.2014.475
Hamidi H., Lu M., Chau K., Anderson L., Fejzo M., Ginther C., Linnartz R., Zubel A., Slamon D.J., Finn R.S.
KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.
Br. J. Cancer 111:1788-1801(2014)

PubMed=25394408; DOI=10.3892/or.2014.3599
Wang C.-F., Zhang W.-W., Fu M.-J., Yang A.-Q., Huang H.-H., Xie J.-M.
Establishment of human pancreatic cancer gemcitabine-resistant cell line with ribonucleotide reductase overexpression.
Oncol. Rep. 33:383-390(2015)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=26216984; DOI=10.1073/pnas.1501605112
Daemen A., Peterson D., Sahu N., McCord R., Du X., Liu B., Kowanetz K., Hong R., Moffat J., Gao M., Boudreau A., Mroue R., Corson L., O'Brien T., Qing J., Sampath D., Merchant M., Yauch R., Manning G., Settleman J., Hatzivassiliou G., Evangelista M.
Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors.
Proc. Natl. Acad. Sci. U.S.A. 112:E4410-E4417(2015)

PubMed=27259358; DOI=10.1074/mcp.M116.058313
Humphrey E.S., Su S.-P., Nagrial A.M., Hochgrafe F., Pajic M., Lehrbach G.M., Parton R.G., Yap A.S., Horvath L.G., Chang D.K., Biankin A.V., Wu J., Daly R.J.
Resolution of novel pancreatic ductal adenocarcinoma subtypes by global phosphotyrosine profiling.
Mol. Cell. Proteomics 15:2671-2685(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=30156359; DOI=10.1111/cas.13783
Sato T., Muramatsu T., Tanabe M., Inazawa J.
Identification and characterization of TGFBI in circulating tumor cell subline from pancreatic cancer cell line.
Cancer Sci. 109:3623-3633(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

Cross-references
Cell line collections AddexBio; C0018010/4923
ATCC; CRL-1469
BCRC; 60284
BCRJ; 0201
CCTCC; GDC0309
CLS; 300228/p635_Panc-1
DSMZ; ACC-783
ECACC; 87092802
IBRC; C10156
IZSLER; BS TCL 49
KCB; KCB 200788YJ
KCB; KCB 200809YJ
KCLB; 21469
NCBI_Iran; C556
RCB; RCB2095
TKG; TKG 0606
Cell line databases/resources CLDB; cl3872
CLDB; cl3873
CLDB; cl3874
CCLE; PANC1_PANCREAS
CCRID; 3111C0001CCC000023
CCRID; 3131C0001000700098
CCRID; 3142C0001000000335
CCRID; 3142C0001000000952
CCRID; 3153C0001000000013
Cell_Model_Passport; SIDM00610
CGH-DB; 180-1
CGH-DB; 9267-4
DepMap; ACH-000164
LINCS_LDP; LCL-1726
Lonza; 818
SKY/M-FISH/CGH; 2001
TOKU-E; 2865
Ontologies BCGO; BCGO_0000122
BTO; BTO:0000304
CLO; CLO_0008381
CLO; CLO_0050102
EFO; EFO_0002713
MCCL; MCC:0000378
Biological sample resources 4DN; 4DNSRDQPS1VU
BioSample; SAMN01821587
BioSample; SAMN03472068
BioSample; SAMN05292439
BioSample; SAMN10987682
ENCODE; ENCBS397PLZ
ENCODE; ENCBS399ENC
ENCODE; ENCBS425ENC
ENCODE; ENCBS465AAA
ENCODE; ENCBS466AAA
ENCODE; ENCBS467AAA
ENCODE; ENCBS470AAA
ENCODE; ENCBS492WPY
ENCODE; ENCBS556WYR
ENCODE; ENCBS761TKL
ENCODE; ENCBS729QZR
ENCODE; ENCBS945URM
Chemistry resources ChEMBL-Cells; CHEMBL3307545
ChEMBL-Targets; CHEMBL614139
PharmacoDB; PANC1_1246_2019
Gene expression databases ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-2770
GEO; GSM206532
GEO; GSM244423
GEO; GSM472938
GEO; GSM472939
GEO; GSM621900
GEO; GSM784698
GEO; GSM887501
GEO; GSM888583
GEO; GSM923421
GEO; GSM945246
GEO; GSM945261
GEO; GSM1024411
GEO; GSM1374806
GEO; GSM1374807
GEO; GSM1374808
GEO; GSM1435699
GEO; GSM1435700
GEO; GSM1435701
GEO; GSM1588613
GEO; GSM1588625
GEO; GSM3333104
GEO; GSM3333105
GEO; GSM3333108
GEO; GSM3333109
Other Wikidata; Q54937550
Polymorphism and mutation databases Cosmic; 707250
Cosmic; 710864
Cosmic; 724643
Cosmic; 730533
Cosmic; 753625
Cosmic; 808171
Cosmic; 868242
Cosmic; 873000
Cosmic; 913307
Cosmic; 918054
Cosmic; 922248
Cosmic; 923171
Cosmic; 932521
Cosmic; 947397
Cosmic; 948377
Cosmic; 949235
Cosmic; 968106
Cosmic; 1006367
Cosmic; 1108335
Cosmic; 1122348
Cosmic; 1198204
Cosmic; 1299304
Cosmic; 1320459
Cosmic; 1366282
Cosmic; 1477432
Cosmic; 1518236
Cosmic; 1534320
Cosmic; 1571781
Cosmic; 1644316
Cosmic; 1609544
Cosmic; 1768264
Cosmic; 2434107
Cosmic; 2546060
Cosmic; 2664043
IARC_TP53; 317
LiGeA; CCLE_087
Proteomic databases PRIDE; PXD002192
PRIDE; PXD003198
Entry history
Entry creation04-Apr-2012
Last entry updated06-Sep-2019
Version number31